Received Oct 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | ASKU | — |
shingles after vaccination; PHN after vaccination; This non-serious case was reported by a physician via call center representative and described the occurrence of shingles in a 55-year-old female patient who received Herpes zoster (Shingrix) (batch number ASKU) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, more than a year after receiving Shingrix, the patient experienced shingles (Verbatim: shingles after vaccination) and post herpetic neuralgia (Verbatim: PHN after vaccination). The patient was treated with gabapentin and valacyclovir. The outcome of the shingles and post herpetic neuralgia were unknown. It was unknown if the reporter considered the shingles and post herpetic neuralgia to be related to Shingrix. It was unknown if the company considered the shingles and post herpetic neuralgia to be related to Shingrix. Additional Information: GSK Receipt Date: 17-SEP-2025 MD reported that her first cousin, approximately 55 years old, had shingles and received the Shingrix vaccine a couple of years later (8 years ago). A year after the vaccination (7 years ago), she experienced breakthrough shingles, which never resolved. She had been on gabapentin for postherpetic neuralgia for 7 years and took Valacyclovir during recurrences, though the frequency of those episodes was unclear.